Rearrangement of 11q23 Chromosome Region in Acute Myeloid Leukemias in Children

MYELOID TUMORS , ,

EV Fleishman1, OI Sokova1, AV Popa1, GA Tsaur2,3,4, LN Konstantinova1, OM Plekhanova2, MV Strigaleva2, ES Nokhrina2, VS Nemirovchenko1, OR Arakaev2,3

1 NN Blokhin Russian Cancer Research Center, 24 Kashirskoye sh., Moscow, Russian Federation, 115478

2 District Children’s Hospital No. 1, 32 S. Deryabinoy str., Yekaterinburg, Russia, 620149

3 Research Institute of Medical Cell Technologies, 22a Karla Marksa str., Yekaterinburg, Russia, 620026

4 The First President of Russia BN Yeltsin Ural Federal University, 19 Mira str., Yekaterinburg, Russia, 620002

For correspondence: Elena Vol’fovna Fleishman, DSci, 24 Kashirskoye sh., Moscow, Russian Federation, 115478; Tel: +7(499)323-57-22; e-mail: flesok@yandex.ru

For citation: Fleishman EV, Sokova OI, Popa AV, et al. Rearrangement of 11q23 Chromosome Region in Acute Myeloid Leukemias in Children. Clinical oncohematology. 2016;9(4):446–55 (In Russ).

DOI: 10.21320/2500-2139-2016-9-4-446-455

ABSTRACT

Aim. To study characteristics of 11q23 involvement, age-specific differences in the incidence of these chromosomal markers in acute myeloid leukemias (AML) in children, and to determine their prognostic significance in patients treated according to the protocols applied in leading Russian pediatric hematological clinics.

Methods. The chromosomal analysis of bone marrow and peripheral blood cells has been performed prior to initiation of treatment in 395 children with primary AML aged from 0 to 16 years. The patients were treated in pediatric hematological clinics of Moscow and Moscow Region and in Yekaterinburg District Children’s Hospital No. 1. Clinical outcomes of 300 followed-up pediatric patients treated with similar modern therapy protocols were analyzed to evaluate the prognostic impact of 11q23/MLL abnormalities. To determine the incidence of 11q23/MLL rearrangements in AML of different age groups, we examined not only children, but also adult patients (n = 212).

Results. In AML, the frequency of changes in the 11q23 region exceeded 40 % in children aged from 0 to 2 years. The frequency decrease with age and in patients over 40 years it was only 2 %. Significant heterogeneity of changes in karyotypes with 11q23/MLL rearrangements was observed: both various translocations with different regions of other chromosomes, and 11q23 deletions were detected. In addition, a great variability of numerical and structural additional chromosomal abnormalities was observed. The 10-year relapse-free survival rates (30.4 ± 6.7 %) and overall survival rates (35.1 ± 7.0 %) in AML with changes in the 11q23 region (n = 61) were significantly lower than those in patients from the intermediate risk group (n = 103): 48.9 ± 5.8 % and 43.8 ± 7.5 %, respectively (p = 0.035). The data are close to those in the high-risk group (n = 44): 35.9 ± 8.1 % and 38.3 ± 7.6 %, respectively. The study failed to confirm the published data that t(9;11) is a more favorable prognostic factor, and that t(6;11) and t(10;11) are less favorable ones than all other 11q23 translocations. Our results did not confirm a negative prognostic effect of additional chromosome abnormalities associated with 11q23 rearrangements.

Conclusion. Pediatric AML patients with 11q23 abnormalities should be included in a high-risk group if therapy is performed according protocols applied in leading hematological centers of Russia.

Keywords: pediatric acute myeloid leukemias, 11q23/MLL rearrangements, risk groups.

Received: May 12, 2016

Accepted: June 15, 2016

Read in PDF (RUS)pdficon

REFERENCES

  1. Mitelman F. Catalog of chromosome aberrations in cancer. 5th edition. Willey-Liss; 1995.
  2. Heim S, Mitelman F. Cancer Cytogenetics. 2nd edition. Wiley-Liss; 1995.
  3. Heim S, Mitelman F. Cancer Cytogenetics. Chromosomal and Molecular Genetic Aberrations of Tumor Cells. 3rd edition. Wiley-Blackwell; 2009.
  4. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Lyon: IARC Press; 2008.
  5. Marshalek R. MLL leukemia and future treatment strategies. Arch Pharm Chem Life Sci. 2015;348(4):1–8. doi: 10.1002/ardp.201400449.
  6. Balgobind BV, Zwaan CM, Pieters R, van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25(8):1239–48. doi: 10.1038/leu.2011.90.
  7. Meyer C, Hoffmann J, Burmeister T, et al. The MLL recombinome of acute leukemias in 2013. Leukemia. 2013;27(11):2165–76. doi: 10.1038/leu.2013.135.
  8. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23/MLL – rearranged acute myeloid leukemia: results of an International retrospective study. Blood. 2009;114(12):2489–96. doi: 10.1182/blood-2009-04-
  9. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322–33.
  10. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United kingdom Medical Research Council trials. Blood. 2010;116(3):354–65. doi: 10.1182/blood-2009-11-
  11. Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group Study. Blood. 1997;90(11):4532–8.
  12. Rubnitz JE, Raimondi SC, Tong X, et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol. 2002;20(9):2302–9. doi: 1200/jco.2002.08.400.
  13. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682–8. doi: 1200/jco.2009.25.6321.
  14. Blum W, Mrozek K, Ruppert AS, et al. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23). Cancer. 2004;101(6):1420–7. doi: 10.1002/cncr.20489.
  15. Karol SE, Coustan-Smith E, Cao X, et al. Prognostic factors in children with acute myeloid leukemia and excellent response to remission induction therapy. Br J Haematol. 2015;168(1):94–101. doi: 1111/bjh.13107.
  16. Coenen EA, Raimondi SC, Harbott J, et al. Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. Blood. 2011;117(26):7102–11. doi: 1182/blood-2010-12-328302.
  17. Schaffer L, McGovan-Jordan J, Schmid M. ISCN. An International System for Human Cytogenetic Nomenclature. Basel: S. Karger; 2013. pp. doi: 10.1002/ajmg.a.35995.
  18. Цаур Г.А., Наседкина Т.В., Попов А.М. и др. Время достижения молекулярной ремиссии как фактор прогноза у детей первого года жизни острым лимфобластным лейкозом. Онкогематология. 2010;2:46–54.
    [Tsaur GA, Nasedkina TV, Popov AM, et al. Time required to achieve molecular remission as a prognostic factor in children of the first year of life with acute lymphoblastic leukemia. Onkogematologiya. 2010;2:46–54. (In Russ)]
  19. Meyer C, Schneider B, Reichel M, et al. Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci USA. 2005;102(2):449–54. doi: 10.1073/pnas.0406994102.
  20. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–81. doi: 1080/01621459.1958.10501452.
  21. Meyer С, Kowarz E, Hofmann J, et al. New insights to the MLL recombinome of acute leukemias. Leukemia. 2009;23(8):1490–9. doi: 10.1038/leu.2009.33.
  22. Ross M, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679–87. doi: 10.1182/blood-2004-03-1154.
  23. Shih L, Liang D, Fu J, et al. Characterization of fusion partner genes in 114 patients with de novo acute myeloid leukemia and MLL rearrangement. Leukemia. 2006;20:218–23. doi: 10.1038/sj.leu.2404024.
  24. Balgobind B, Hollink I, Reinhardt D, et al. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Eur J Cancer. 2010;46(10):1892–9. doi: 10.1016/j.ejca.2010.02.019.
  25. Shimada A, Taki T, Tabuchi K, et al. Tandem duplications of MLL and FLT3 are correlated with poor prognoses in pediatric acute myeloid leukemia: a study of the Japanese childhood AML Cooperative Study Group. Pediatr Blood Cancer. 2008;50(2):264–9. doi: 10.1002/pbc.21318.
  26. Steudel C, Wermke M, Schaich M, et al. Comparative analysis of MLL partial tandem duplication and FLT3 internal tandem duplication mutations in 956 adult patients with acute myeloid leukemia. Gene Chromos Cancer. 2003;37(3):237–51. doi: 10.1002/gcc.10219.
  27. Rege-Cambrin G, Giugliano E, Michaux L, et al. Trisomy 11 in myeloid malignancies is associated with internal tandem duplication of both MLL and FLT3 genes. Haematologica. 2005;90(2):262–4.
  28. Swansbury GJ, Slater R, Bain BJ, et al. Hematological malignancies with t(9;11)(p21-22;q23) – laboratory and clinical study of 125 cases. European 11q23 Workshop participants. Leukemia. 1998;12(5):792–800. doi: 10.1038/sj.leu.2401014.
  29. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML10 and 12. J Clin Oncol. 2010;28(16):2674–81. doi: 10.1200/jco.2009.24.8997.
  30. Pession A, Masetti R, Rizzari C, et al. Results of the ALEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood. 2013;122(2):170–8. doi: 10.1182/blood-2013-03-491621.
  31. Schoch C, Schnittger S, Klaus M, et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosome, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102(7):2395–402. doi: 10.1182/blood-2003-02-0434.
  32. Tamai H, Yamaguchi H, Hamaguchi H, et al. Clinical features of adult acute leukemia with 11q23 abnormalities in Japan: A co-operative multicenter study. Int J Hematol. 2008;87(2):193–200. doi: 10.1007/s12185-008-0034-
  33. Balgobind BV, Zwaan CM, Reinhardt D, et al. High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome. Leukemia. 2010;24(12):2048–55. doi: 10.1038/leu.2010.211.
  34. Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942–9. doi: 10.1038/leu.2010.47.
  35. Ho PA, Alonzo TA, Gerbing RB, et al. High EVI1 expression is associated with MLL rearrangements and predicts decreased survival. Br J Haematol. 2013;62(5):670–7. doi: 1111/bjh.12444.
  36. Chen C, Armstrong S. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond. Exp Hematol. 2015;43(8):673–84. doi: 10.1016/j.exphem.2015.05.012.
  37. Nguyen AT, Taranova O, He J, Zhang Y. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis. Blood. 2011;117(25):6912–22. doi: 10.1182/blood-2011-02-
  38. Stein EM, Garcia-Manero G, Rizzieri DA, et al. The DOT1L Inhibitor EPZ-5676: safety and activity in relapsed/refractory patients with MLL-rearranged leukemia. [Internet] Available from: http://www.epizyme.com/wp-content/uploads/2014/12/ASH-EPZ-5676-Presentation-Final.pdf. (accessed 10.05.2016).